Arrowpoint Investment Partners Chooses SS&C for Fund Administration

2025-02-25 IDOPRESS

WINDSOR,Conn.,Feb. 24,2025 --SS&C Technologies Holdings,Inc. (Nasdaq: SSNC) today announced that Arrowpoint Investment Partners,Singapore's new multi-strategy hedge fund investment firm,has selected SS&C GlobeOp to administer its flagship $1 billion multi-strategy fund. The fund currently leverages 18 portfolio managers in Hong Kong SAR and Singapore across various strategies.

"Our philosophy is to integrate multiple strategies across our teams by leveraging technology to generate consistent,high-quality,risk-adjusted returns," said Woon Young Jeong,Chief Operating Officer of Arrowpoint. "We needed an administrator who was deeply familiar with multiple asset classes,complex fee structures,and managing reporting requirements for investors of multi-manager vehicles. SS&C's cutting-edge technology and professional and knowledgeable support team make it an ideal partner to service our fund."

Arrowpoint was founded by Jonathan Xiong,the former co-CEO of Millennium's Asia operations. Rather than managing trading teams as separate entities,Arrowpoint integrates its fundamental and quant strategies across equities,fixed income and commodities to gain more precise control over performance. The firm focuses on investments in Asia.

"We are pleased to work with Arrowpoint Investment Partners as they grow their innovative fund," said Michael Li,Managing Director,Head of SS&C GlobeOp,APAC. "As the hedge fund market evolves,multi-strategy vehicles attract much investor interest. These vehicles can be complex to manage,as multiple asset classes,fee structures and reporting requirements are involved. We look forward to working with Arrowpoint to alleviate those operational stresses so the team can focus on investing."

Learn more about SS&C's multi-manager fund solutions here.

About Arrowpoint Investment Partners

Arrowpoint is an investment firm building a differentiated Asia-focused,multi-strategy platform. Learn more at https://arrowpointfund.com/

About SS&C Technologies

SS&C is a global provider of services and software for the financial services and healthcare industries. Founded in 1986,SS&C is headquartered in Windsor,Connecticut,and has offices around the world. More than 22,000 financial services and healthcare organizations,from the world's largest companies to small and mid-market firms,rely on SS&C for expertise,scale and technology.

Additional information aboutSS&C (Nasdaq: SSNC) is available at www.ssctech.com.

Follow SS&C onTwitter,LinkedIn and Facebook.

Disclaimer: This article is reproduced from other media. The purpose of reprinting is to convey more information. It does not mean that this website agrees with its views and is responsible for its authenticity, and does not bear any legal responsibility. All resources on this site are collected on the Internet. The purpose of sharing is for everyone's learning and reference only. If there is copyright or intellectual property infringement, please leave us a message.

Newest

1Cangxi County Holds 2026 New Year's Cultural Performance for the Public

Cangxi County Holds 2026 New Year's Cultural Performance for the Public

2The First Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

The First Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

3The Second Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

The Second Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

4Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Singapore College of Traditional Chinese Medicine Sign Strategic Cooperation Framework Agreement on TCM Education and Exchange

Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Singapore College of Traditional Chinese Medicine Sign Strategic Cooperation Framework Agreement on TCM Education and Exchange

5Tianjiang Pharmaceutical, a Subsidiary of China TCM, Participates in the 4th CACM Specialized Disease Collaboration Platform Annual Conference & 10th Jiangsu Traditional Chinese Medicine Academic Conference

Tianjiang Pharmaceutical, a Subsidiary of China TCM, Participates in the 4th CACM Specialized Disease Collaboration Platform Annual Conference & 10th Jiangsu Traditional Chinese Medicine Academic Conference

6Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Federation of Chinese Medicine & Acupuncture Societies of Australia Sign Strategic Cooperation Framework Agreement

Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Federation of Chinese Medicine & Acupuncture Societies of Australia Sign Strategic Cooperation Framework Agreement

©copyright 2009-2020 Singapore Info Map